Rallybio reveals Phase 1 MAD data for RLYB116: >93% free C5 reduction at 100 mg weekly; cash runway extended to 3Q 2025

Rallybio Corp

100 mg weekly dose of RLYB116 achieved >93% mean reduction in free C5 at Day 29; >99% reduction 24h post-first dose.
RLYB116 half-life >300 hours; low inter-subject variability; all adverse events mild, most common injection-site reaction (60% in 100mg cohort).
Company deprioritizes Phase 2 start in gMG, focusing on manufacturing to improve tolerability and widen indications.
Cash runway guidance updated: current resources expected to fund operations into Q3 2025.
RLYB212 for FNAIT continues as lead program; near-term RLYB116 investments directed to process improvements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.